The HepatoPancreaticoBiliary Resection Arginine Immunomodulation (PRIMe) Trial
The HepatoPancreaticoBiliary Resection Arginine Immunomodulation (PRIMe) Trial
NCT ID: NCT04549662 Phase: NA Status: COMPLETED Enrollment: 45 Completion: 2024-02-12
Conditions
Hepatopancreaticobiliary (HPB) Malignancy, Surgery
Interventions
Active A, Active B, Lipid bolus, Placebo oil
Summary
This is a randomized controlled blinded superiority trial to evaluate the impact of perioperative immunosupplementation on immune function following resection for hepatopancreaticobiliary (HPB) malignancy.
Primary Outcome
Natural killer (NK) cell killing